<?xml version="1.0" encoding="UTF-8"?>
<p id="Par27">The therapeutic history revealed that patients in treatment with lamivudine + adefovir, never changed this schedule. Instead, patients receiving tenofovir or entecavir, were previously exposed to lamivudine + adefovir in 16/20 (80.0%) and 1/12 (8.3%) of cases, respectively.</p>
